S3)

Analysis ID	Pooled SMD (95% CI)
Amagai−2722−F1D	−1.830 (−2.783, −0.877)
Beljanski−2766−F4A	−0.405 (−1.395, 0.585)
Beljanski−2766−F4C	−0.422 (−1.412, 0.569)
Chang−2834−F1A	−2.295 (−3.121, −1.469)
Chang−2834−F1B	−2.825 (−3.713, −1.938)
Hakime−3031−T1	−5.555 (−7.751, −3.359)
Iguchi−3097−F1	−2.067 (−3.784, −0.351)
Oosterwijk−Wakka−3327−T1	−1.100 (−2.510, 0.309)
Roulin−3427−F4Ai	−5.009 (−7.530, −2.488)
Roulin−3427−F4Aii	−3.585 (−5.586, −1.584)
Roulin−3427−F6A	−3.354 (−5.277, −1.431)
Takeuchi−3550−F3A	−4.004 (−6.152, −1.855)
Takeuchi−3550−F4A	−2.067 (−3.603, −0.532)
Takeuchi−3551−F4A	−3.419 (−5.363, −1.474)
Takeuchi−3551−F4B	−4.417 (−6.715, −2.118)
Wang−3619−F1A	−3.130 (−4.119, −2.141)
Yuen−3674−F1A	−4.084 (−5.897, −2.271)
Zhang−3685−F1AB	−4.713 (−6.462, −2.965)
Subgroup Renal Cell Carcinoma (RCC) (I^2=75% , P=0.000)	**−2.792 (−3.461, −2.123)**
Auclair−2740−F3A	−1.051 (−1.774, −0.328)
Subgroup Acute Myelogenous Leukemia (AML) (I^2=NA , P=NA)	**−1.051 (−1.774, −0.328)**
Bareford−2756−F5A	−0.807 (−1.826, 0.212)
Carter−2827−F3	−4.762 (−6.186, −3.338)
Nukatsuka−3320−F2A	−3.508 (−5.069, −1.947)
Sabir−3434−T1	−2.106 (−3.215, −0.998)
Tran−3586−F5B	−2.229 (−3.994, −0.465)
Valabrega−3602−F7A	−0.756 (−1.663, 0.151)
Subgroup Breast Cancer (I^2=84% , P=0.000)	**−2.286 (−3.527, −1.045)**
Beljanski−2766−F4B	−0.614 (−1.617, 0.389)
Rausch−3398−F2A	−3.955 (−5.407, −2.504)
Subgroup Pancreatic Cancer (I^2=93% , P=0.000)	**−2.242 (−5.515, 1.031)**
Beljanski−2767−F5A	−1.668 (−2.884, −0.451)
Beljanski−2767−F5B	−1.287 (−2.364, −0.211)
Benten−2771−F6A	−1.668 (−2.884, −0.452)
Chen−2844−F6A	−0.844 (−2.025, 0.337)
Chen−2845−F6A	−0.864 (−2.047, 0.320)
Eicher−2930−F3A	−1.319 (−2.400, −0.238)
Hikita−3060−SF3	−1.055 (−2.071, −0.039)
Huynh−3093−F1Bi	−7.752 (−10.727, −4.778)
Huynh−3093−F1Bii	−3.077 (−4.615, −1.539)
Huynh−3093−F5A	−3.120 (−4.223, −2.017)
Huynh−3094−F2B	−2.644 (−3.658, −1.630)
Huynh−3094−F2C	−2.013 (−2.922, −1.103)
Huynh−3094−F2D	−1.001 (−1.786, −0.215)
Lee−3200−F1B	−0.925 (−2.229, 0.379)
Li−3214−F4A	−1.710 (−2.790, −0.630)
Liu−3225−F5A	−3.037 (−4.117, −1.957)
Liu−3225−F5B	−4.696 (−6.107, −3.286)
Newell−3311−F7A	−0.723 (−1.788, 0.342)
Ou−3330−F6Ai	−3.795 (−6.473, −1.117)
Ou−3330−F6Aii	−0.829 (−2.497, 0.839)
Ou−3331−F6Ai	−1.587 (−3.421, 0.248)
Ou−3331−F6Aii	−0.979 (−2.672, 0.715)
Piguet−3364−F1B	−1.524 (−2.871, −0.177)
Tai−3547−F5A	−2.211 (−3.648, −0.775)
Tang−3558−F3A	−5.519 (−7.507, −3.532)
Tang−3559−F2B	−6.059 (−8.192, −3.926)
Wang−3618−F9A	−1.840 (−3.493, −0.186)
Wang−3625−T1A	−5.389 (−7.497, −3.280)
Wang−3625−T1B	−3.523 (−5.088, −1.957)
Subgroup Hepatocellular Carcinoma (I^2=75% , P=0.000)	**−2.269 (−2.762, −1.776)**
Carter−2827−F1	−1.855 (−2.903, −0.807)
Carter−2827−F2	−0.544 (−1.437, 0.348)
Carter−2827−F4	−1.753 (−2.633, −0.874)
Carter−2827−F5	−0.558 (−1.452, 0.335)
Dredge−2913−F6A	−1.064 (−2.051, −0.077)
Martinelli−3263−T1A	−13.120 (−17.280, −8.961)
Nukatsuka−3320−F2B	−2.878 (−4.276, −1.480)
Subgroup Non−Small−Cell Lung Carcinoma (NSCLC) (I^2=86% , P=0.000)	**−2.032 (−3.174, −0.891)**
Huang−3080−F4B	−1.690 (−2.711, −0.669)
Kuo−3171−F4B	−0.967 (−1.894, −0.041)
Mamluk−3256−F3B	−5.978 (−7.652, −4.305)
Plastaras−3373−F6Ai	−0.185 (−1.427, 1.057)
Plastaras−3373−F6Bi	−0.419 (−1.305, 0.467)
Ricci−3407−SF5A	−1.630 (−2.936, −0.324)
Subgroup Colorectal Cancer (I^2=87% , P=0.000)	**−1.703 (−2.972, −0.435)**
Huynh−3092−F2B	−3.574 (−5.262, −1.886)
Subgroup Gastrointestinal Stromal Tumour (GIST) (I^2=NA , P=NA)	**−3.574 (−5.262, −1.886)**
Lee−3193−F5A	−1.340 (−2.225, −0.454)
Lee−3193−F5B	−3.355 (−4.597, −2.114)
Lee−3193−F5C	−8.795 (−11.409, −6.181)
Leguerney−3202−F2A	−1.429 (−2.411, −0.447)
Liu−3226−F6A	−0.937 (−2.129, 0.255)
Lopez−Fauqued−3235−F4A	−0.916 (−2.220, 0.387)
Mangiameli−3258−F2C	−1.486 (−2.593, −0.379)
Metzner−3281−F6A	−2.037 (−3.244, −0.829)
Tran−3586−F5A	−3.482 (−5.679, −1.284)
Subgroup Melanoma (I^2=81% , P=0.000)	**−2.292 (−3.255, −1.328)**
Lemasson−3205−F2B	−0.404 (−1.462, 0.654)
Lemasson−3206−F3	−1.976 (−2.732, −1.220)
Siegelin−3491−F3Aiii	−6.076 (−9.360, −2.792)
Subgroup High−Grade Glioma (I^2=85% , P=0.002)	**−2.154 (−4.075, −0.232)**
Lian−3217−F1Di	−2.995 (−4.580, −1.409)
Lian−3217−F1Dii	−2.663 (−4.158, −1.167)
Subgroup Prostate Cancer (I^2=0% , P=0.765)	**−2.819 (−3.907, −1.731)**
Matsumura−3268−F4C	−4.853 (−6.800, −2.907)
Matsumura−3268−F4D	−8.346 (−12.419, −4.272)
Matsumura−3268−F4E	−4.152 (−5.794, −2.511)
Subgroup Ovarian Cancer (I^2=43% , P=0.173)	**−5.045 (−6.779, −3.311)**
Pignochino−3361−F7A	−4.591 (−6.336, −2.845)
Subgroup Osteosarcoma (Pediatric) (I^2=NA , P=NA)	**−4.591 (−6.336, −2.845)**
Sugiyama−3538−F5A	−4.065 (−5.343, −2.788)
Sugiyama−3538−F6B	−2.073 (−3.105, −1.041)
Subgroup Cholangiocarcinoma (I^2=82% , P=0.017)	**−3.032 (−4.983, −1.081)**
Tesei−3567−F5	−1.016 (−2.218, 0.187)
Yang−3665−F4A	−2.443 (−3.422, −1.464)
Yang−3665−SF2D	−3.647 (−5.247, −2.048)
Yang−3665−T1ii	−3.715 (−4.938, −2.492)
Subgroup Gastric Cancer (I^2=74% , P=0.009)	**−2.658 (−3.863, −1.452)**
Yadav−3661−F4A	−0.729 (−2.009, 0.551)
Yadav−3661−F4B	−0.996 (−2.310, 0.319)
Subgroup Squamous Cell Carcinoma (I^2=0% , P=0.776)	**−0.859 (−1.776, 0.058)**
Yang−3664−F6A	−2.787 (−4.162, −1.411)
Subgroup Medulloblastoma (Pediatric) (I^2=NA , P=NA)	**−2.787 (−4.162, −1.411)**
Overall (I^2=79% , P=0.000)	**−2.396 (−2.682, −2.110)**